The present disclosure relates to neutralizing epitopes of tenascin-C, and binding domains specific therefor, such as antibodies or binding fragments thereof, pharmaceutical compositions comprising them, and the aforementioned antibodies, binding fragments or therapeutics, especially in the treatment of inflammatory diseases. It relates to the use of the composition. [Selection] Figure 2本開示は、テネイシンCの中和エピトープ、およびそれに特異的な結合ドメイン、例えば抗体またはその結合断片、それを含む医薬組成物、ならびに治療、特に炎症性疾患の治療における前述の抗体、結合断片または組成物の使用に関する。【選択図】図2